Prohibits state from buying any prescription drug from a drug manufacturer at price over lowest price paid for the drug by United States Department of Veterans Affairs. Exempts managed care programs funded through Medi-Cal. Fiscal Impact: Potential for state savings of an unknown amount depending on (1) how the measure’s implementation challenges are addressed and (2) the responses of drug manufacturers regarding the provision and pricing of their drugs.
Chart depicts total fundraising by all committees primarily formed for and against Prop 61.Totals are updated daily with contributions from Power Search and adjustments from the most recent Political Reform Division analysis.
Showing the 10 largest contributions to committees formed primarily for and against Prop 61 in the election cycle when it appeared on the ballot. Contributions in earlier election cycles and contributions between allied committees are excluded. For more information on funding for ballot measure campaigns, visit the Power Search campaign finance search engine.
A YES vote on this measure means: State agencies would generally be prohibited from paying more for any prescription drug than the lowest price paid by the U.S. Department of Veterans Affairs for the same drug.
A NO vote on this measure means: State agencies would continue to be able to negotiate the prices of, and pay for, prescription drugs without reference to the prices paid by the U.S. Department of Veterans Affairs.
For background on Proposition 61, an analysis by the legislative analyst, endorsements for and against the measure, and more...
Prop. 61, The California Drug Price Relief Act, would require all prescription drugs purchased by the State of California to be priced at or below the price paid for the same drug by the U.S. Dept. of Veterans Affairs, which pays by far the lowest price of any federal agency.
Experts say Prop. 61 would: increase prescription prices, reduce patient access to needed medicines, produce more bureaucracy and lawsuits that cost taxpayers millions, and hurt veterans by increasing their prescription costs. Strongly opposed by California Medical Association, California NAACP, California Taxpayers Association, Ovarian Cancer Coalition of Greater California, Veterans of Foreign Wars (VFW), Department of California. www.NoProp61.com